The drug Kalydeco has been approved to treat patients with one of the mutations that cause cystic fibrosis. FDA's Stephen Spielberg, M.D., Ph.D, tells how this targeted treatment represents how personalized medicine will revolutionize health care.

The drug Kalydeco has been approved to treat patients with one of the mutations that cause cystic fibrosis. FDA's Stephen Spielberg, M.D., Ph.D, tells how this targeted treatment represents how personalized medicine will revolutionize health care.

The FDA approved Kalydeco (kuh-LYE-deh-koh) for a segment of the CF population, those ages 6 and older with the G551D mutation of cystic fibrosis.

The FDA approved Kalydeco (kuh-LYE-deh-koh) for a segment of the CF population, those ages 6 and older with the G551D mutation of cystic fibrosis.

Pinterest
Search